uniQure N.V. (Netherland, NASDAQ: QURE)
uniQure developed a breakthrough gene therapy technology but faced significant challenges fund raising, attracting corporate partnerships and establishing access to EU commercial infrastructure as a preparation for product launch. uniQure hired Extera to support its internal BD team and to lead the BD efforts, sign strategic deal as soon as possible.
Extera helped uniQure close gaps in its story to include the negotiation of critical in-licensing agreements. Discussions with top decision makers in relevant pharmaceutical companies resulted in an interest from several potential buyers. This interest turned into a strategic transaction with Chiesi Pharmaceuticals which became a critical factor in the company’s successful listing on the NASDAQ.
$58m upfront payment, in-licensing agreement, substantial equity investment and $400m EU licensing & supply agreement